Scleral melt following Retisert intravitreal fluocinolone implant

Intravitreal fluocinolone acetonide implant (Retisert) has a high potency, a low solubility, and a very short duration of action in the systemic circulation, enabling the steroid pellet to be small and reducing the risk of systemic side effects. Scleral melt has not been reported as a possible compl...

Descripción completa

Detalles Bibliográficos
Autores principales: Georgalas, Ilias, Koutsandrea, Chrysanthi, Papaconstantinou, Dimitrios, Mpouritis, Dimitrios, Petrou, Petros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4257017/
https://www.ncbi.nlm.nih.gov/pubmed/25489235
http://dx.doi.org/10.2147/DDDT.S66634
Descripción
Sumario:Intravitreal fluocinolone acetonide implant (Retisert) has a high potency, a low solubility, and a very short duration of action in the systemic circulation, enabling the steroid pellet to be small and reducing the risk of systemic side effects. Scleral melt has not been reported as a possible complication of Retisert implant. The authors describe the occurrence of scleral melt 18 months after the implantation of fluocinolone acetonide implant in a 42-year-old Caucasian woman. To the authors’ knowledge, this is the first report of this possible complication.

Ejemplares similares